| [1] |
Adsay V. Ki67 labeling index in neuroendocrine tumors of the gastrointestinal and pancreatobiliary tract: to count or not to count is not the question, but rather how to count.Am J Surg Pathol, 2012, 36(12): 1743-1746.
|
| [2] |
Yachida S, Vakiani E, White CM, et al.Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.Am J Surg Pathol, 2012, 36(2): 173-184.
|
| [3] |
Scarpa A, Mantovani W, Capelli P, et al.Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients.Mod Pathol, 2010, 23(6): 824-833.
|
| [4] |
Panzuto F, Boninsegna L, Fazio N, et al.Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.J Clin Oncol, 2011, 10, 29(17): 2372-2377.
|
| [5] |
Dasari A, Yao JC.Gastrointestinal neuroendocrine tumors: slow but steady progress.Oncology, 2014, 28(9): 201362.
|
| [6] |
Gilbert JA.Lanreotide delays progression of neuroendocrine tumours.Lancet Oncol, 2014, 15(10): 418.
|
| [7] |
Engstrom PF, Lavin PT, Moertel CG, et al.Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor.J Clin Oncol, 1984, 2(11): 1255-1259.
|
| [8] |
Dahan L, Bonnetain F, Rougier P, et al.Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710.Endocr Relat Cancer, 2009, 16(4): 1351-1361.
|
| [9] |
Kulke MH, Bergsland EK, Ryan DP, et al.Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.J Clin Oncol, 2006, 24(22): 3555-3561.
|
| [10] |
Thearle MS, Freda PU, Bruce JN, et al.Temozolomide(Temodar®)and capecitabine(Xeloda®)treatment of an aggressive corticotroph pituitary tumor.Pituitary, 2011, 14(4): 418-424.
|
| [11] |
Hainsworth JD.Evolving understanding and management of poorly differentiated neuroendocrine tumors.Clin Adv Hematol Oncol, 2013, 11(12): 805-806.
|
| [12] |
Rinke A, Müller HH, Schade-Brittinger C, et al.PROMID Study Group.Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.J Clin Oncol, 2009, 27(28): 4656-4663.
|
| [13] |
Caplin ME, Pavel M, Ĉwikla JB, et al.CLARINET Investigators.Lanreotide in metastatic enteropancreatic neuroendocrine tumors.N Engl J Med, 2014, 371(3): 224-233.
|
| [14] |
Pavel ME, Hainsworth JD, Baudin E, et al.RADIANT-2 Study Group.Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrinetumours associated withcarcinoid syndrome(RADIANT-2): a randomised, placebo-controlled, phase 3 study.Lancet, 2011, 378(9808): 2005-2012.
|
| [15] |
Yao JC, Shah MH, Ito T, et al.Everolimus for advanced pancreatic neuroendocrine tumors.RAD001 in Advanced Neuroendocrine Tumors, Third Trial(RADIANT-3)Study Group.N Engl J Med, 2011, 364(6): 514-523.
|
| [16] |
Raymond E, Dahan L, Raoul JL, et al.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.N Engl J Med, 2011, 364(6): 501-513.
|